Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cystic fibrosis offer hidden protection against COVID-19?

NCT ID NCT04863573

Knowledge-focused Sponsor: Queen's University, Belfast Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

Researchers in the UK are following 1,000 people with cystic fibrosis (CF), including children and adults, to see how many develop antibodies to the virus that causes COVID-19 over two years. They will take blood samples every six months to measure antibody levels after natural infection and after vaccination. The team will also track lung function, flare-ups, and other health changes to understand how COVID-19 affects CF. This study aims to answer whether people with CF are naturally protected or simply avoiding infection through careful precautions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Observational study with no intervention; participants receive standard care and blood tests.
What this could lead to
If the study succeeds, it could clarify whether people with cystic fibrosis are naturally protected from COVID-19 and how vaccination shapes their immune response.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may vary by age, geography, and treatment, and the findings may not apply to all people with cystic fibrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity will be eligible to participate in the study. The study population is expected to be representative of the general CF population.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity Exclusion Criteria: * Refusal to give informed consent * Contraindication to venepuncture. Participants already enrolled in a clinical trial are eligible for enrollment in this study. Inclusion in CAR-CF should not preclude enrollment in other observational clinical trial studies or clinical trials of an investigational medicinal product (CTIMP).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 Cystic fibrosis

Contacts and locations

Locations

  • Birmingham Women'S and Children'S Nhs Foundation Trust

    Birmingham, England, B4 6NH, United Kingdom

  • Cardiff & Vale University Lhb

    Cardiff, Wales, CF14 4HH, United Kingdom

  • Cardiff & Vale University Lhb

    Cardiff, Wales, United Kingdom

  • King'S College Hospital Nhs Foundation Trust

    London, England, SE5 9RS, United Kingdom

  • Leeds Teaching Hospitals Nhs Trust

    Leeds, England, LS9 7TF, United Kingdom

  • NHS Greater Glasgow and Clyde

    Glasgow, Scotland, G12 0XH, United Kingdom

  • Nottingham University Hospitals Nhs Trust

    Nottingham, England, NG7 2UH, United Kingdom

  • Queens University Belfast

    Belfast, Northern Ireland, United Kingdom

  • Royal Brompton & Harefield Nhs Foundation Trust

    London, England, SW3 6NP, United Kingdom

  • University Hospital Southampton Nhs Foundation Trust

    Southampton, Engladn, SO16 6YD, United Kingdom

  • University Hospitals Birmingham Nhs Foundation Trust

    Birmingham, England, B15 2GW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.